Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Single Unit Red Blood Cell Transfusion Is a Safe and Effective Alternative to Double Unit Transfusion in Hematologic Malignancies

Zelia Bowman, MD, Aaron Cumpston, PharmD, Michael Craig, MD, Sijin Wen, PhD, Peter L. Perrotta, MD, Janice Ahn, MD, Naomi Fei, MD, Nilay A. Shah, MD, Abraham Sebastian Kanate, MD

Blood (2016) 128 (22): 3855.

https://doi.org/10.1182/blood.V128.22.3855.3855

Published: 2016

Journal Articles

Cost and Efficacy of Upfront Plerixafor Versus a “Just-in-Time” (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization

Lauren Westfall Veltri, MD, Aaron Cumpston, PharmD, Alexandra Shillingburg, PharmD, Christopher Lipinski, Sijin Wen, PhD, Sonia Leadmon, Kathy Watkins, MT, Lab Technician, Michael David Craig, MD, Mehdi Hamadani, MD, Abraham S. Kanate, MD

Blood (2014) 124 (21): 1127.

https://doi.org/10.1182/blood.V124.21.1127.1127

Published: 2014

Journal Articles

Predictors and Impact Of 30-Day Readmissions On Patient Outcomes and Healthcare Costs After Allogeneic Hematopoietic Cell Transplantation

Abraham Sebastian Kanate, MD, Sherri Rauenzahn, MD, Sonia Leadmon, BS, Quoc V. Truong, MD, Aaron Cumpston, PharmD, Londia Goff, Kim Evans, Jianjun Zhang, Sijin Wen, Michael Craig, Mehdi Hamadani, MD

Blood (2013) 122 (21): 1718.

https://doi.org/10.1182/blood.V122.21.1718.1718

Published: 2013

Journal Articles

Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

Farhad Ravandi, Jeffrey L. Jorgensen, Deborah A. Thomas, Susan O’Brien, Rebecca Garris, Stefan Faderl, Xuelin Huang, Sijin Wen, Jan A. Burger, Alessandra Ferrajoli, Partow Kebriaei, Richard E. Champlin, Zeev Estrov, Pramoda Challagundla, Sa A. Wang, Rajyalakshmi Luthra, Jorge E. Cortes, Hagop M. Kantarjian

Blood (2013) 122 (7): 1214–1221.

https://doi.org/10.1182/blood-2012-11-466482

Published: 2013

Includes: Supplemental data

Journal Articles

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

Xavier C. Badoux, Michael J. Keating, Sijin Wen, Bang-Ning Lee, Mariela Sivina, James Reuben, William G. Wierda, Susan M. O'Brien, Stefan Faderl, Steven M. Kornblau, Jan A. Burger, Alessandra Ferrajoli

Blood (2011) 118 (13): 3489–3498.

https://doi.org/10.1182/blood-2011-03-339077

Published: 2011

Includes: Supplemental data

Journal Articles

Results of a Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) Combination Therapy In Patients with Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS)

Apostolia Maria Tsimberidou, MD, PhD, William G. Wierda, MD, PhD, Sijin Wen, Ph.D., William Plunkett, PhD, Susan O'Brien, MD, Thomas J. Kipps, MD, PhD, Jeffrey A. Jones, MD, MPH, Hagop M. Kantarjian, Michael J. Keating, MD

Blood (2010) 116 (21): 923.

https://doi.org/10.1182/blood.V116.21.923.923

Published: 2010

Journal Articles

Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia: The M. D. Anderson Cancer Center Experience

Dolly G Aguilera, Christos Vaklavas, MD, Apostolia-Maria Tsimberidou, MD, PhD, Sijin Wen, PhD, L. Jeffrey Medeiros, MD, Seth J. Corey

Blood (2008) 112 (11): 5068.

https://doi.org/10.1182/blood.V112.11.5068.5068

Published: 2008

Journal Articles

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

Constantine S. Tam, Susan O'Brien, William Wierda, Hagop Kantarjian, Sijin Wen, Kim-Anh Do, Deborah A. Thomas, Jorge Cortes, Susan Lerner, Michael J. Keating

Blood (2008) 112 (4): 975–980.

https://doi.org/10.1182/blood-2008-02-140582

Published: 2008

Journal Articles

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Alessandra Ferrajoli, Bang-Ning Lee, Ellen J. Schlette, Susan M. O'Brien, Hui Gao, Sijin Wen, William G. Wierda, Zeev Estrov, Stefan Faderl, Evan N. Cohen, Changping Li, James M. Reuben, Michael J. Keating

Blood (2008) 111 (11): 5291–5297.

https://doi.org/10.1182/blood-2007-12-130120

Published: 2008

Journal Articles

Prognostic Significance of Tissue Necrosis Factor-Alpha in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes.

Apostolia-Maria Tsimberidou, MD, PhD, Elihu Estey, MD, Maher Albitar, MD, Sijin Wen, MS, Mark Brandt, BS, Sherry Pierce, RN, Hagop Kantarjian, MD, Razelle Kurzrock, MD

Blood (2007) 110 (11): 4263.

https://doi.org/10.1182/blood.V110.11.4263.4263

Published: 2007

Journal Articles

Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Analysis of 2083 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Susan O’Brien, M.D., Peter McLaughlin, M.D., Sijin Wen, M.S., William Wierda, M.D., Ph.D., Hagop M. Kantarjian, M.D., John Manning, M.D., Susan Lerner, M.S., Mark Hess, B.B.A., Emil J. Freireich, M.D., Michael J. Keating, M.D.

Blood (2006) 108 (11): 2790.

https://doi.org/10.1182/blood.V108.11.2790.2790

Published: 2006

Journal Articles

Prognostic Significance of β-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Hagop M. Kantarjian, M.D., Michael J. Keating, M.D., Susan O’Brien, M.D., Sijin Wen, M.S., Jorge Cortes, M.D., Francis Giles, M.D., Charles Asa Koller, M.D., Guillermo Garcia-Manero, M.D., Sherry Pierce, B.S.N., Mark Brandt, Emil J. Freireich, M.D., Elihu H. Estey, M.D.

Blood (2006) 108 (11): 802.

https://doi.org/10.1182/blood.V108.11.802.802

Published: 2006

Journal Articles

A Prognostic Score for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Analysis of 2189 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Peter McLaughlin, M.D., Susan O’Brien, M.D., Sijin Wen, M.S., William G. Wierda, M.D., Ph.D., John Manning, M.D., Susan Lerner, M.S., Mark A. Hess, Hagop Kantarjian, M.D., Emil J. Freireich, M.D., Michael J. Keating, M.D.

Blood (2006) 108 (11): 2783.

https://doi.org/10.1182/blood.V108.11.2783.2783

Published: 2006

Journal Articles

The Effect of Initial Therapy Choice in Determining Long Term Survival in Patients with Chronic Lymphocytic Leukemia (CLL).

Constantine S. Tam, MBBS, Sijin Wen, MS MA, Kim-Anh Do, PhD, Susan Lerner, MS, William G. Wierda, MD PhD, Susan O’Brien, MD, Michael J. Keating, MBBS

Blood (2006) 108 (11): 4976.

https://doi.org/10.1182/blood.V108.11.4976.4976

Published: 2006

Journal Articles

Genomic Aberrations in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Count: Analysis of 1694 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Peter McLaughlin, M.D., Susan O’Brien, M.D., Sijin Wen, M.S., William G. Wierda, M.D., Ph.D., John T. Manning, M.D., Lynne V. Abruzzo, M.D., Ph.D., Susan Lerner, M.S., Mark A. Hess, B.B.A., Hagop M. Kantarjian, M.D., Emil J. Freireich, M.D., Michael J. Keating, M.D.

Blood (2006) 108 (11): 4958.

https://doi.org/10.1182/blood.V108.11.4958.4958

Published: 2006

Journal Articles

Clinical Outcomes and Prognostic Factors in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy with or without Stem Cell Transplantation.

Apostolia-Maria Tsimberidou, MD, PhD, Susan O’Brien, MD, BA, Issa Khouri, MD, BS, Francis J. Giles, MD, Hagop M. Kantarjian, MD, Sijin Wen, MS, Susan C. Smith, BS, Susan Lerner, MS, BA, Emil J. Freireich, MD, BS, Michael J. Keating, MD

Blood (2005) 106 (11): 2097.

https://doi.org/10.1182/blood.V106.11.2097.2097

Published: 2005

Journal Articles

Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy.

Apostolia-Maria Tsimberidou, MD, PhD, Daniel Catovsky, MD, Ellen Schlette, MD, Susan O’Brien, MD, BA, Hagop Kantarjian, MD, William G. Wierda, MD, PhD, Sijin Wen, MS, Susan Lerner, MS, BA, Michael J. Keating, MD

Blood (2005) 106 (11): 922.

https://doi.org/10.1182/blood.V106.11.922.922

Published: 2005

NARROW

Single Unit Red Blood Cell Transfusion Is a Safe and Effective Alternative to Double Unit Transfusion in Hematologic Malignancies

Cost and Efficacy of Upfront Plerixafor Versus a “Just-in-Time” (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization

Predictors and Impact Of 30-Day Readmissions On Patient Outcomes and Healthcare Costs After Allogeneic Hematopoietic Cell Transplantation

Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

Results of a Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) Combination Therapy In Patients with Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS)

Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia: The M. D. Anderson Cancer Center Experience

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Prognostic Significance of Tissue Necrosis Factor-Alpha in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes.

Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Analysis of 2083 Patients.

Prognostic Significance of β-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.

A Prognostic Score for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Analysis of 2189 Patients.

The Effect of Initial Therapy Choice in Determining Long Term Survival in Patients with Chronic Lymphocytic Leukemia (CLL).

Genomic Aberrations in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Count: Analysis of 1694 Patients.

Clinical Outcomes and Prognostic Factors in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy with or without Stem Cell Transplantation.

Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only